Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.
The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.
The samples, which include non-small cell lung cancer samples, will be screened for cancer fusions, copy number variations, SNPs, and insertions and deletions.
The Chinese guideline recommends the use of the Septin-9 DNA methylation assay as the standard of care for early colorectal cancer screening.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.